Skip to main content
OpenTrials
Completed

NCT Number: NCT05976204

Prognostic Value of NLR, TLR, and ALC in Predicting ToF Primary Repair Outcome

Tetralogy of Fallot (ToF) were cyanotic congenital heart disease with chronic hypoxia which increases the risk of exacerbated inflammatory response in ToF primary repair. Various studies have recently shown inflammatory biomarkers to predict morbidity and mortality in hypoxemic patients, but they are not readily available and expensive.This study aims to compare the prognostic value of neutrophil-lymphocyte ratio (NLR), absolute lymphocyte count (ALC), and thrombocyte-lymphocyte ratio (TLR) in predicting ToF primary repair outcomes. This was a retrospective observational study on ToF primary repair in National Cardiovascular Center Harapan Kita between Januari 2020 until December 2022. Preoperative NLR, ALC, and TLR were derived from blood test obtained <14 days before surgery. The primary endpoints were redo surgery, 30-day mortality, and complications. The secondary endpoints were hospital length of stay (HLOS) and postoperative LOS.

Completed

Looking for future studies?

Notify Me

Key information

About this study

This was a retrospective observational study on tetralogy of Fallot (ToF) primary repair in National Cardiovascular Center Harapan Kita between Januari 2020 until December 2022. The preoperative demographic data included were patients' gender, age, weight, oxygen saturation, and associated diagnosis other than ToF. The preoperative data of complete blood count and differential count must be tested from the most recent peripheral blood samples taken no later than 14 days before the surgery. The data obtained were the number of days of the most recent blood test including the leukocyte count, percentage neutrophil, percentage and absolute lymphocyte count, thrombocyte count, as well as the derived variables such as neutrophil lymphocyte ratio (NLR) ratio and thrombocyte lymphocyte ratio (TLR). The intraoperative data included were the use of cardiopulmonary bypass (CPB), CPB time, aortic cross-clamp (AOX) time, and the total duration of surgery. Patients were evaluated and followed-up for any complications and postoperative mortality during the same hospital stay until discharge. Patients were then followed up for any cause of mortality within 30 days postoperative.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All patients with ToF and any other associated cardiac anomalies, who underwent ToF primary repair and had a complete blood cell count with differential count available preoperatively

Exclusion criteria

  • Surgery other than ToF primary repair
  • Association with other procedures (except patent ductus arteriosus/PDA ligation, patent foramen ovale/PFO or atrial septal defect/ASD closure, or pulmonary arteries enlargement)
  • Preoperative hemodynamic instability
  • Suspected or confirmed infection with prior antibiotic administration during the same hospital admission
  • Absence of complete blood count with differential count

Treatment and study plan

ToF primary repair

Procedure

ToF primary repair for patients with ToF

Primary outcomes

  1. Number of Patients Requiring Redo surgery

    Time frame: From the initial primary ToF until the discharge of the patients or until 2 weeks after the operation, whichever came first

    Redo surgery was defined as additional or corrective surgery after the initial primary ToF repair within the same hospital admission.

  2. Mortality

    Time frame: Until 30 days postoperative

    Mortality intraoperative or postoperative

  3. Complications (categorized as mild, moderate, severe)

    Time frame: From the initial primary ToF until the discharge of the patients or until 2 weeks after the operation, whichever came first

    Complication was defined as any adverse events that arised during the operation or postoperative until the discharge of the patient.

Secondary outcomes

  1. Hospital Length of Stay

    Time frame: From the initial primary ToF until the discharge of the patients or until 12 weeks after the operation, whichever came first

    Hospital length of stay (HLOS) was defined as the duration of stay in the hospital from the initial admission to discharge.

  2. Postoperative Length of Stay

    Time frame: From the initial primary ToF until the discharge of the patients or until 12 weeks after the operation, whichever came first

    Longer postoperative LOS was defined as hospitalization of more than 5 days from the period of surgery until postoperative discharge (based on our center).

Sponsors and collaborators

Lead sponsor

National Cardiovascular Center Harapan Kita Hospital Indonesia

Other

Registry information

Official study title

Prognostic Value of Neutrophil-Lymphocyte Ratio (NLR), Absolute Lymphocyte Count (ALC), and Thrombocyte-Lymphocyte Ratio (TLR) in Predicting the Outcomes of Tetralogy of Fallot Primary Repair

Important dates

Study start
2020
Primary completion
2022
Study completion
2023
First posted
Aug 4, 2023
Registry last updated
Aug 8, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.